Trade Report: The Nektar Therapeutics (NKTR) CEO Howard W. Robin Sold 87,500 Shares

The Nektar Therapeutics (NKTR) CEO Howard W. Robin Sold 87,500 Shares

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 87,500 shares of the stock in a transaction that occurred on Tuesday, October 4th. The stock was sold at an average price of $17.06, for a total value of $1,492,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Howard W. Robin also recently made the following trade(s): On Thursday, September 1st, Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock. The shares were sold at an average price of $17.83, for a total value of $1,560,125.00. On Tuesday, August 16th, Howard W. Robin sold 11,817 shares of Nektar Therapeutics stock. The shares were sold at an average price of $17.56, for a total value of $207,506.52.

Nektar Therapeutics (NASDAQ:NKTR) opened at 16.81 on Monday. The firm has a 50-day moving average price of $18.14 and a 200-day moving average price of $15.92. The company’s market capitalization is $2.30 billion. Nektar Therapeutics has a 12 month low of $9.92 and a 12 month high of $19.98.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.03. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 68.30%. The firm had revenue of $32.77 million for the quarter, compared to the consensus estimate of $34.17 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The company’s revenue was up 44.6% on a year-over-year basis. On average, equities analysts anticipate that Nektar Therapeutics will post ($1.11) earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on NKTR shares. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a report on Tuesday, July 19th. Brean Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Nektar Therapeutics in a report on Friday, August 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $21.00 price target (up from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $21.75.

Several large investors have recently modified their holdings of NKTR. Norges Bank bought a new stake in shares of Nektar Therapeutics during the fourth quarter valued at about $35,961,000. Prudential Financial Inc. boosted its stake in shares of Nektar Therapeutics by 4.9% in the first quarter. Prudential Financial Inc. now owns 322,973 shares of the biopharmaceutical company’s stock valued at $4,441,000 after buying an additional 15,100 shares during the period. BlackRock Inc. boosted its stake in shares of Nektar Therapeutics by 74.8% in the first quarter. BlackRock Inc. now owns 9,013 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 3,858 shares during the period. BlackRock Group LTD boosted its stake in shares of Nektar Therapeutics by 8.9% in the first quarter. BlackRock Group LTD now owns 175,205 shares of the biopharmaceutical company’s stock valued at $2,408,000 after buying an additional 14,340 shares during the period. Finally, BlackRock Fund Advisors boosted its stake in shares of Nektar Therapeutics by 1.7% in the first quarter. BlackRock Fund Advisors now owns 10,029,475 shares of the biopharmaceutical company’s stock valued at $137,905,000 after buying an additional 171,759 shares during the period. Institutional investors and hedge funds own 96.91% of the company’s stock.

About Nektar Therapeutics

Related posts

Leave a Comment